LipoFIT Analytic GmbH, a Regensburg, Germany-based developer of diagnostic tools to assess the risk of developing atherosclerosis, raised €4m in growth financing.
The round was led by SHS Gesellschaft für Beteiligungsmanagement, a growth investor located in Tübingen, Germany, KfW Bankengruppe (ERP Startfonds), and Bayern Kapital.
In exchange for their investment, the new partners will receive around a 50% stake in the company.
The proceeds will enable the company to transform an analytical technology developed by researchers at the University of Regensburg into diagnostic products.
The technology of LipoFIT permits the entire analysis of a person’s metabolism enabling physicians working from complex clinical findings to make quick and tuned diagnoses, thereby considerably improving patients’ chances of recovery.
The company’s clients include major corporations in the pharmaceuticals sector, as well as several university clinics.
Established in 2004 as a spin-off of the University of Regensburg, the company currently employs ten staff members.
It was announced that Volker Pfahlert, formerly Chief Executive at Dräger Medical AG, will join LipoFIT as COO in charge of strategy, marketing and sales while Fritz Huber will remain as CEO.